Thursday, October 6, 2016

Emend


Emend is a brand name of aprepitant, approved by the FDA in the following formulation(s):


EMEND (aprepitant - capsule; oral)



  • Manufacturer: MERCK

    Approval date: March 26, 2003

    Strength(s): 125MG [RLD], 80MG


  • Manufacturer: MERCK

    Approval date: June 30, 2006

    Strength(s): 40MG

Has a generic version of Emend been approved?


No. There is currently no therapeutically equivalent version of Emend available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Emend. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Medical use for tachykinin antagonists
    Patent 5,538,982
    Issued: July 23, 1996
    Inventor(s): Hagan; Russell M. & Bunce; Keith T.
    Assignee(s): Glaxo Group Limited
    The present invention relates to the use of tachykinin antagonists, including substance P antagonists and other neurokinin antagonists, in the treatment of emesis. Also described are novel tachykinin antagonists of formula (I), processes for their preparation, pharmaceutical compositions containing them and their medical use. ##STR1## wherein R represents the ring A ##STR2## or 2-pyridinyl or 2-pyridinyl-N-oxide; R.sup.1 is selected from halogen atoms and C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl, and S(O).sub.n C.sub.1-4 alkyl groups; R.sup.2 and R.sup.3, which may be the same or different, each independently are selected from hydrogen and halogen atoms and C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl and cyano groups; n represents zero, 1 or 2; and pharmaceutically acceptable salts and solvates thereof.
    Patent expiration dates:

    • July 23, 2013
      ✓ 
      Patent use: TREATMENT OR PREVENTION OF EMESIS




  • Morpholine and thiomorpholine tachykinin receptor antagonists
    Patent 5,719,147
    Issued: February 17, 1998
    Inventor(s): Dorn; Conrad P. & Finke; Paul E. & Hale; Jeffrey J. & MacCoss; Malcolm & Mills; Sander G. & Shah; Shrenik K. & Chambers; Mark Stuart & Harrison; Timothy & Ladduwahetty; Tamara & Williams; Brian John
    Assignee(s): Merck & Co., Inc.
    Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
    Patent expiration dates:

    • April 17, 2015
      ✓ 
      Patent use: TREATMENT OR PREVENTION OF EMESIS
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Morpholine and thiomorpholine tachykinin receptor antagonists
    Patent 6,048,859
    Issued: April 11, 2000
    Inventor(s): Dorn; Conrad P. & Finke; Paul E. & Hale; Jeffrey J. & Maccoss; Malcolm & Mills; Sander G. & Shah; Shrenik K. & Chambers; Mark Stuart & Harrison; Timothy & Ladduwahetty; Tamara & Williams; Brian John
    Assignee(s): Merck & Co., Inc.
    Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
    Patent expiration dates:

    • June 29, 2012
      ✓ 
      Patent use: TREATMENT OR PREVENTION OF EMESIS




  • Polymorphic form of a tachykinin receptor antagonist
    Patent 6,096,742
    Issued: August 1, 2000
    Inventor(s): Crocker; Louis & McCauley; James
    Assignee(s): Merck & Co., Inc.
    This invention is concerned with a novel polymorphic form of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)-phenyl)-ethoxy)-3-(S)-(4-fluoro)phe nyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine which is a tachykinin receptor antagonist useful in the treatment or prevention of disorders of the central nervous system, inflammatory diseases, pain or migraine, asthma, and emesis. The instant polymorphic form has advantages over the other known forms of 2-(R)-(1-(R)-(3,5-bis(trifluoro-methyl)-phenyl)ethoxy)-3-(S)-(4-fluoro)phe nyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine in terms of thermodynamic stability and suitability for inclusion in pharmaceutical formulations.
    Patent expiration dates:

    • July 1, 2018
      ✓ 
      Patent use: TREATMENT OR PREVENTION OF EMESIS
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Morpholine and thiomorpholine tachykinin receptor antagonists
    Patent 6,235,735
    Issued: May 22, 2001
    Inventor(s): Dorn; Conrad P. & Hale; Jeffrey J & Finke; Paul E. & Maccoss; Malcolm & Mills; Sander G. & Shah; Shrenik K. & Chambers; Mark Stuart & Ladduwahetty; Tamara & Harrison; Timothy & Williams; Brian John
    Assignee(s): Merck & Co., Inc.
    Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
    Patent expiration dates:

    • June 29, 2012
      ✓ 
      Patent use: PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT


    • June 29, 2012
      ✓ 
      Patent use: PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING




  • Medical use for tachykinin antagonists
    Patent 7,214,692
    Issued: May 8, 2007
    Inventor(s): Hagan; Russell Michael & Bunce; Keith Thomas
    Assignee(s): Glaxo Group Limited
    The present invention relates to the use of tachykinin antagonists, including substance P antagonists and other neurokinin antagonists, in the treatment of emesis. Also described are novel tachykinin antagonists of formula (I), processes for their preparation, pharmaceutical compositions containing them and their medical use. wherein R represents the ring A or 2-pyridinyl or 2-pyridinyl-N-oxide; R1 is selected from halogen atoms and C1-4alkyl, C1-4alkoxy, trifluoromethyl, and S(O)nC1-4alkyl groups; R2 and R3, which may be the same or different, each independently are selected from hydrogen and halogen atoms and C1-4alkyl, C1-4alkoxy, trifluoromethyl and cyano groups; n represents zero, 1 or 2; and pharmaceutically acceptable salts and solvates thereof.
    Patent expiration dates:

    • September 18, 2012
      ✓ 
      Patent use: TREATMENT OR PREVENTION OF EMESIS



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • March 19, 2013 - LABELING REVISIONS RELATED TO CLINICAL STUDIES

See also...

  • Emend Consumer Information (Drugs.com)
  • Emend Consumer Information (Wolters Kluwer)
  • Emend Consumer Information (Cerner Multum)
  • Emend Advanced Consumer Information (Micromedex)
  • Emend AHFS DI Monographs (ASHP)
  • Aprepitant Consumer Information (Wolters Kluwer)
  • Aprepitant Consumer Information (Cerner Multum)
  • Aprepitant Advanced Consumer Information (Micromedex)
  • Aprepitant/Fosaprepitant Dimeglumine AHFS DI Monographs (ASHP)
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)